Dificid® (fidaxomicin) – Expanded orphan indication, New formulation
January 27, 2020 - Merck announced the FDA approval of Dificid (fidaxomicin), in adult and pediatric patients aged 6 months and older for the treatment of Clostridioides difficile-associated diarrhea (CDAD).
Download PDF
